Docoh
Loading...
Sign up Log in

AIM AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Company profile

Ticker
AIM
Exchange
NYSE
Website
aimimmuno.com
CEO
Thomas Equels
Employees
Incorporated
Delaware
Location
Florida
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Seagen ...
Former names
HEMISPHERX BIOPHARMA INC
SEC CIK
0000946644
Corporate docs
IRS number
520845822

AIM stock data

(
)

News

Pro users get this 30m faster
AIM ImmunoTech Reports Phase 2a Human Challenge Trial To Test Its Drug Ampligen As Intranasal Antiviral Prophylactic Therapy
9 Jul 21
AIM ImmunoTech Inc. (NYSE:AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a
AIM ImmunoTech Says Completes All Treatments In Phase 1 Human Safety Study Of Intranasal Administration Of Ampligen
21 Jun 21
AIM ImmunoTech Inc. (NYSE:AIM) today announced that all subjects have completed treatment in the Company's Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential
AIM ImmunoTech Highlights Ampligen Featured in Peer-Reviewed Journal Cancers As A Potential Therapy For Cancer Patients With SARS-CoV-2
14 Jun 21
AIM ImmunoTech Inc. (NYSE:AIM) today announced that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential
AIM ImmunoTech Reports Completed Dosing Of Cohort 3 In Phase 1 Study To Assess Safety, Tolerability, Biological Activity Of Ampligen As An Intranasal Therapy
26 May 21
AIM ImmunoTech Q1 EPS $(0.08) Up From $(0.22) YoY
18 May 21

Press releases

Pro users get this 30m faster
AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy
9 Jul 21
OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a
AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET
6 Jul 21
OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent
AIM ImmunoTech's Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2
14 Jun 21
OCALA, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) today announced that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed
AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen
27 May 21
AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial
26 May 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 May 21
29 Jul 21
31 Dec 21

Financial summary

Financial statements Chart AIM financial data
Quarter (USD)
 Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 48.77M 48.77M 48.77M 48.77M 48.77M 48.77M
Cash burn (monthly) (positive/no burn) (positive/no burn) 1.25M 1.3M 1.02M 846.92K
Cash used (since last report) n/a n/a 4.94M 5.14M 4.02M 3.35M
Cash remaining n/a n/a 43.83M 43.63M 44.75M 45.42M
Runway (months of cash) n/a n/a 35.1 33.6 44.1 53.6

Beta Read what these cash burn values mean

Recent insider trades

AIM insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
16 Jul 21 Equels Thomas K. Common Stock Buy Aquire P No No 1.92 15,625 30K 225,255
25 Feb 21 Stewart Appelrouth Common Stock Buy Aquire P No No 2.35 10,638 25K 92,538
24 Feb 21 Equels Thomas K. Common Stock Buy Aquire P No No 2.26 11,062 25K 209,630
17 Dec 20 Equels Thomas K. Common Stock Buy Aquire P No No 1.72 14,535 25K 198,568
9 Dec 20 Ellen M Lintal Options Common Stock Grant Aquire A No No 1.85 75,000 138.75K 75,000
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

AIM institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
 Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
 Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
Largest transactions
 Shares Bought/sold Change
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Baxter International • Pfizer • Canada • Astrazeneca • Novartis • Glaxosmithkline
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: alleviate, article, assessment, augment, Ave, bind, Biopharma, Branford, Cagliari, capacity, Centre, challenge, CHDR, covid, CRL, curb, decided, della, di, Dipartimento, EC, embedded, EPS, EU, evolution, favorable, formal, GPPharm, gravity, greater, hamster, Hedging, Hemispherx, HollisterStier, impede, inhibition, instrument, Italy, Leiden, length, lethal, Leyden, magnitude, moment, Monserrato, mouse, MTA, notification, notify, NV, obsolete, opposed, PA, paving, Penn, Perry, Peter, Phoenix, Pii, pipeline, protein, provision, rare, Receptor, redundancy, reinstated, repeated, Rodino, roof, Scienze, storage, strategic, subsidiary, superior, Syrian, tax, twelve, unanticipated, UNICA, upregulation, Videx, Vita, Warrington, workforce
Removed: abstract, accelerating, adjusted, Affirmative, agreeable, Answer, applying, atomized, atomizer, attributed, BioLife, Biologic, biologically, Breach, calendar, capable, ceramic, Certificate, chance, choice, choose, Codification, combating, comparative, compliant, conclusion, connection, conserve, controlled, convert, converting, copy, counterclaim, covering, credit, curtail, deep, defendant, deliver, denied, derecognized, Diba, diminishing, discovery, discretionary, divided, dread, Easement, economic, effected, emergency, estate, eventually, expedient, extending, FIFO, fixed, guaranteed, half, hindsight, Iliad, implementation, inception, incurred, indirectly, intending, ir, Japan, larger, largest, Latifi, lead, leasing, lessee, lesser, lower, making, malignancy, manufacturer, measure, mediation, mist, monetary, mortgage, mutual, NIID, obtainable, office, optional, order, package, particle, pattern, practical, preapproval, predominantly, preliminary, priority, producing, promised, prospective, proving, qualify, quote, racing, ratio, reach, reaching, reacquisition, real, realizable, recast, reclassified, recognize, recognizing, redeem, redeemed, redemption, reduce, reinsurance, remained, replace, reproducible, reserve, retained, retroactive, ROU, safely, scope, session, set, settle, sheet, Shionogi, specialist, spending, split, stockholder, stored, subsequently, supplement, Targeted, therefrom, thereof, timeline, today, Topic, trade, unamortized, unfavorable, unissued, unpaid, unused, updated, utilizing, variable, volume, VWAP, withheld
From filing 10-Q 2021 Q1

Financial reports

View all
10-Q
2021 Q1
Quarterly report
17 May 21
10-K
2020 FY
Annual report
30 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q/A
2020 Q1
Quarterly report (amended)
14 May 20
10-Q
2020 Q1
Quarterly report
13 May 20
10-K
2019 FY
Annual report
30 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19

Current reports

View all
8-K
Regulation FD Disclosure
14 Jul 21
8-K
Entry into a Material Definitive Agreement
13 Jul 21
8-K
Other Events
14 Jun 21
8-K
Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive
27 May 21
8-K
Regulation FD Disclosure
18 May 21
8-K
Other Events
6 May 21
8-K
AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo
3 May 21
8-K
Completion of Acquisition or Disposition of Assets
23 Apr 21
8-K
Entry into a Material Definitive Agreement
19 Apr 21
8-K
Other Events
9 Apr 21

Registration and prospectus

View all
S-8
Registration of securities for employees
1 Jul 21
424B5
Prospectus supplement for primary offering
18 Aug 20
S-8
Registration of securities for employees
3 Aug 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
10 Mar 20
424B5
Prospectus supplement for primary offering
3 Mar 20
424B4
Prospectus supplement with pricing info
26 Sep 19
S-1/A
IPO registration (amended)
24 Sep 19
S-1/A
IPO registration (amended)
24 Sep 19
S-1/A
IPO registration (amended)
23 Sep 19

Proxies

View all
DEF 14A
Definitive proxy
11 Aug 20
DEF 14A
Definitive proxy
20 Aug 19
DEF 14A
Definitive proxy
23 Apr 19
PRE 14A
Preliminary proxy
5 Apr 19
DEF 14A
Definitive proxy
3 Aug 18
PRE 14A
Preliminary proxy
19 Jul 18
DEF 14A
Definitive proxy
17 Jul 17
DEFA14A
Additional proxy soliciting materials
13 Jul 16
DEF 14A
Definitive proxy
26 Jun 16
PRER14A
Preliminary revised proxy
8 Jun 16

Other

View all
EFFECT
Notice of effectiveness
26 Sep 19
UPLOAD
Letter from SEC
25 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
UPLOAD
Letter from SEC
23 Sep 19
UPLOAD
Letter from SEC
11 Sep 19
CORRESP
Correspondence with SEC
5 Sep 19
EFFECT
Notice of effectiveness
15 Feb 19
CORRESP
Correspondence with SEC
10 Feb 19

Ownership

View all
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
16 Jul 21
4
AIM ImmunoTech / STEWART APPELROUTH ownership change
25 Feb 21
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
24 Feb 21
SC 13G/A
AIM ImmunoTech / Hudson Bay Capital Management ownership change
8 Feb 21
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
17 Dec 20
4
AIM ImmunoTech / III PETER W. RODINO ownership change
11 Dec 20
4
AIM ImmunoTech / ELLEN M LINTAL ownership change
11 Dec 20
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
13 Nov 20
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
3 Sep 20
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
21 Aug 20

Patents

APP
Utility
Compositions for Cancer Therapy and Methods
1 Jul 21
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately.
APP
Utility
Compositions for Cancer Therapy and Methods
24 Jun 20
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately.

Reddit threads

View all